Company Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -84.58% |
| 6 Months: | -68.51% |
| 3 Months: | -10.02% |
| 1 Month: | -3.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.03 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SNGX Soligenix, Inc. PHARMA | 0.38 | -0.53 | $8.27M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 312.49K | 910.60K | 1.42M | 2.79M | 816.29K | 1.10M | 3.88M | 2.63M | 3.16M | 2.96M | 1.33M | 990.97K | 1.82M | 1.12M | 1.73M | 1.38M | 1.14M | 1.54M | 1.25M | 924.55K | 505.29K | 608.81K | 147.59K | 214.82K | 186.20K | 188.06K | 228.64K | 166.14K | 257.18K | 206.93K | 130.44K | 117.03K | 2.34K | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 66.63K | 281.62K | 383.66K | 678.18K | 288.89K | 283.12K | 828.86K | 398.65K | 817.51K | 329.21K | 243.57K | 313.80K | 347.92K | 140.85K | 231.87K | 144.12K | 216.86K | 458.15K | 289.45K | 95.05K | 141.95K | 222.17K | 25.23K | 10.51K | 19.93K | 95.85K | 35.34K | 36.70K | 31.14K | 22.91K | 20.00K | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.03M | 2.76M | 2.58M | 3.47M | 2.88M |
| Operating Income | -1.86M | -1.59M | -1.70M | -5.14M | -1.56M | -2.03M | -1.27M | -1.91M | -1.01M | -1.50M | -1.74M | -2.32M | -969.62K | -2.39M | -1.59M | -1.92M | -2.30M | -2.16M | -2.77M | -8.47M | -2.81M | -1.81M | -2.23M | -2.99M | -3.36M | -4.19M | -3.40M | -3.08M | -2.15M | -1.63M | -1.78M | -2.12M | -1.74M | -1.87M | - | -3.03M | -2.76M | -2.58M | -3.47M | -2.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.03M | -2.76M | -2.58M | -3.47M | -2.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.95M | -2.70M | -2.53M | -3.40M | -2.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -409.11K | - | - | - | - | - |
| Net Income | -6.56M | -3.33M | -948.52K | -4.35M | -4.57M | -3.98M | 2.77M | -1.15M | -92.78K | -1.67M | -1.73M | -2.31M | -963.09K | -2.38M | -1.56M | -1.86M | -1.64M | -2.12M | -2.72M | -7.58M | -2.78M | -1.79M | -2.36M | -1.90M | -3.59M | -4.35M | -2.39M | -3.31M | -1.05M | -1.61M | -1.66M | -1.92M | -1.64M | -1.72M | - | -2.95M | -2.70M | -2.53M | -2.90M | -2.82M |
| Diluted EPS | - | - | - | -0.21 | -0.19 | -0.15 | -0.45 | -0.59 | -0.19 | -0.49 | -0.32 | -0.41 | -0.17 | -0.27 | -0.18 | -0.11 | - | - | - | - | - | - | -0.06 | -0.05 | -0.09 | -1.52 | -0.83 | -1.15 | -0.36 | -3.56 | -2.56 | -2.91 | -1.31 | -0.78 | - | -0.97 | -0.82 | -0.58 | - | -0.28 |
| R&D Expense | 1.22M | 1.03M | 1.21M | 5.09M | 1.03M | 1.44M | 1.26M | 1.43M | 827.83K | 1.18M | 1.22M | 1.78M | 605.72K | 1.80M | 1.17M | 1.39M | 1.64M | 1.85M | 2.27M | 2.70M | 2.17M | 1.27M | 1.31M | 1.94M | 2.24M | 1.75M | 2.05M | 1.79M | 946.45K | 762.70K | 826.01K | 1.10M | 501.16K | 968.69K | - | 1.94M | 1.68M | 1.58M | - | 1.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.95M | 7.66M | 3.14M | 3.22M | 7.04M | 8.77M | 10.45M | 5.43M | 5.24M | 4.63M | 2.36M | - | 250.00K | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 550.82K | 742.05K | 119.37K | 0 |
| Gross Profit | 309.23K | 5.55M | 551.54K | 679.87K | 1.73M | 1.89M | 2.02M | 1.12M | 643.73K | 1.06M | 538.50K | - | -300.82K | -742.05K | -119.37K | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 13.81M | 6.93M | 9.35M | 11.85M |
| Operating Income | -7.88M | -2.96M | -4.69M | -7.16M | -10.76M | -7.11M | -5.71M | -7.59M | -9.06M | -10.54M | -18.59M | - | -14.11M | -7.67M | -9.46M | -11.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -14.11M | -7.67M | -9.46M | -11.84M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 904.50K | 822.61K | 49.13K | -213.97K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -14.95M | -7.91M | -8.68M | -11.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -1.15M | -1.77M | -409.11K | -506.62K |
| Net Income | - | -2.38M | -4.16M | -10.06M | -6.71M | -7.83M | -3.25M | -7.15M | -8.90M | -9.36M | -17.69M | - | -13.80M | -6.14M | -8.27M | -11.08M |
| Diluted EPS | - | - | - | -0.65 | -0.43 | -3.00 | -1.34 | -1.16 | - | - | -0.64 | - | -76.96 | -12.66 | -4.98 | -2.14 |
| R&D Expense | 5.99M | 6.27M | 2.61M | 5.07M | 5.09M | 5.40M | 4.30M | 5.51M | 6.75M | 8.12M | 9.80M | 8.19M | 7.94M | 3.31M | 5.22M | 7.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.27M | 8.22M | 4.71M | 8.27M | 6.95M | 7.39M | 10.27M | 9.55M | 10.49M | 7.78M | 19.89M | - | 14.28M | 9.80M | 8.97M | 9.24M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.85M | 9.51M | 8.83M | 8.85M |
| Cash & Equivalents | 7.69M | 7.45M | 6.00M | 3.36M | 5.86M | 5.53M | 4.92M | 8.77M | 7.81M | 8.98M | 5.42M | 18.68M | - | 13.36M | 8.45M | 7.82M | 7.94M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 138.89K | 115.13K | 0 | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 4.21M | 6.32M | 16.15M | - | 16.75M | 7.27M | 4.85M | 3.94M |
| Current Liabilities | - | 1.91M | 1.43M | 1.15M | 10.04M | 7.11M | 7.41M | 2.87M | 3.23M | 4.21M | 6.31M | 6.08M | - | 16.52M | 6.15M | 4.85M | 3.70M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 9.86M | - | 1.01M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.24M | 3.49M | 1.48M | 358.14K |
| Total Equity | 8.17M | 7.36M | 6.79M | 3.55M | -1.77M | -153.89K | -18.31K | 7.40M | 6.32M | 6.28M | 1.46M | 3.74M | - | -2.47M | 2.52M | 4.12M | 5.29M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 181.79K | 648.64K | 2.51M | 10.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.73M | -1.95M | 2.64M | -4.46M | -2.47M | -5.39M | -4.98M | -6.51M | -7.24M | -7.51M | -11.45M | - | -12.65M | -8.60M | -8.40M | -10.27M |
| Investing Cash Flow | -336.42K | -152.66K | -4.75K | -17.73K | -300.87K | -22.10K | -7.16K | -26.35K | -925 | -24.71K | -7.15K | - | -13.07K | 0 | 0 | -5.88K |
| Financing Cash Flow | 5.83M | 649.36K | - | 6.97M | 2.44M | 4.80M | 8.84M | 5.57M | 8.42M | 4.01M | 24.68M | - | 76.82K | 3.66M | 7.76M | 10.39M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | -11.79K | -13.07K | - | - | -5.88K |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | - | - | -12.66M | -8.60M | -8.40M | -10.27M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -12.59M | -4.94M | -641.53K | 116.64K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 15.9% | 72.5% | 17.5% | 21.1% | 24.6% | 21.5% | 19.3% | 20.7% | 12.3% | 22.9% | 22.8% | - | -120.3% | - | - | - |
| Operating Margin % | -404.5% | -38.6% | -149.2% | -222.0% | -152.8% | -81.1% | -54.6% | -139.8% | -172.8% | -227.7% | -787.7% | - | -5,642.4% | - | - | - |
| Net Margin % | - | -31.0% | -132.4% | -312.0% | -95.2% | -89.3% | -31.1% | -131.6% | -169.8% | -202.1% | -749.7% | - | -5,519.3% | - | - | - |
| ROE % | - | -35.0% | -117.2% | 568.4% | 4,358.3% | 42,772.6% | -43.9% | -113.1% | -141.7% | -642.1% | -472.7% | - | 558.5% | -243.4% | -200.7% | -209.4% |
| ROCE % | -107.1% | -43.6% | -132.1% | 404.4% | 6,992.9% | 38,834.9% | -77.2% | -120.2% | -144.2% | -720.4% | -134.6% | - | 630.5% | -210.5% | -229.8% | -214.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 0.96% | 209.51K | $77.52K |
| 2 | Jane Street Group, LLC | 0.95% | 207.49K | $76.77K |
| 3 | Xtx Topco Ltd | 0.72% | 157.12K | $58.13K |
| 4 | Geode Capital Management, LLC | 0.55% | 120.27K | $44.50K |
| 5 | Vanguard Capital Management LLC | 0.37% | 81.00K | $29.97K |
| 6 | Virtu Financial LLC | 0.28% | 60.90K | $22.53K |
| 7 | Vanguard Fiduciary Trust Co | 0.25% | 53.91K | $19.95K |
| 8 | Northern Trust Corporation | 0.17% | 38.05K | $14.08K |
| 9 | Morgan Stanley | 0.02% | 3.59K | $1.33K |
| 10 | Jones Financial Companies, L.L.L.P. | 0.01% | 1.24K | $457 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNGX
Soligenix Stock Price Forecast. Should You Buy SNGX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5IbTU5NFMxWThkcXF5aG8yR2FoS3dodlV3UDQwTV9GZnlYUnZGNU13dHVCWmJXT3VuZ3ZqRUxQMDQ5RXI3ZlVTZQ?oc=5" target="_blank">Soligenix Stock Price Forecast. Should You Buy SNGX?</a> <…
Soligenix (SNGX) Stock Price, News & Analysis - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1MZktKaXpFWXYtZF9SU2lUMlNGYi1JYldXZjlaWFdWdmJnejMzNm1aVnMybVVXMzRFbGVzOHhfU1AxbmR4ZHVzaEt3eWo4SksxUEU3VUJJeEYtdw?oc=5" target="_blank">Soligenix (SNGX) Stock Price, News & Analysis…
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQOFIydUZkTzg0cDQxaVB0cHFrOC1icFVMT1Y4c0FNRk9iUWw4NXZIYlBQU3o2Xzk1aFpWVWV4UDMyY2dya1h4WjI2ZEs3UVdIWUI4TXFKUHNrc2xJcktTS2laMGR5aWNOMGw3Z1d3em1uQk9KUVZ3UWk2SGFRdW9Ebk9lZ3M5cjVCaE5idm…
SNGX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5XMi1IRzREdlNGTFJfYTVaUlMtNW1KejJWYjV5bGtqcFRIRGZmRmpFTzNHUzFpX3lDX0NOdUprTU5kWkc3SUE?oc=5" target="_blank">SNGX</a> <font color="#6f6f6f">Finviz</font>…
SNGX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9mM0VmZXh4blpsSm5jVkRYT3Z2NlhlR2ptMmdyXzM3N0lmYTlYMkNua20zYVlLdEFOT0xOc1gzcDJHM2NOeGR0YnhSOWJzakxkdVBDRlRyQmp3c2JhdEFYeUpHemdIZ3ZIYi15Q2xpYnBsVnc5RXk3SEJ3?oc=5" target="_blank">SNG…
Thermostable vaccine tech flagged for Congo’s Bundibugyo Ebola outbreak - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPQTFpVmhjWWpIekR0R1lWMGd6TWNIQ2ZpQTlCM2dqX1hWZXBHR0pSWkxqeFkzLURMb090NllxN1RiRFhNbmEzUFl2QTMwQV9jaEoxaHZYQTZITl9oYldqZzhrbDlzN3o3RlQxMnJ3LXBCRXQxOXhRMVFsb1lJRVhyR2l5ZGhVWE1LY3F3Tm…
SNGX — Frequently Asked Questions
What is the current share price of Soligenix, Inc. (SNGX)?
As of 2026-09-19 21:16 PDT, Soligenix, Inc. (SNGX) trades at $0.38 on NasdaqCM. Its 52-week range is $0.28 to $4.96.
What is the market capitalisation of SNGX?
Soligenix, Inc. (SNGX) has a market capitalisation of $8.27M on NasdaqCM.
What is the P/E ratio of SNGX?
SNGX trades at a trailing price-to-earnings (P/E) ratio of -0.53. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.21.
Is SNGX a good stock to buy?
This page provides a data-driven analysis of Soligenix, Inc. (SNGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.